Skip to main content
27514 search results for:

Hodgkin Lymphoma 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-04-2024 | Online First

    Unusual Presentation of Non-Hodgkin Lymphoma of Two Cases: Case Report

    Lymphomas are a diverse group of neoplastic disorders arising primarily in lymph nodes. They have been majorly classified into Hodgkin and Non-Hodgkin lymphomas(NHL). NHL can be of B, T and Null cell categories having further subtypes based on …

  2. 23-04-2024 | Hodgkin Lymphoma | Online First

    Cardiovascular screening outcomes in the Dutch survivorship care program for Hodgkin lymphoma survivors

    Hodgkin lymphoma (HL) is a curable malignancy that is usually diagnosed at young ages, most frequently between 20 and 40 years [ 1 ]. Combination treatment regimens of chemotherapy (CT) and radiotherapy (RT) currently result in 80–90% cure rates [ …

  3. Open Access 01-12-2024 | Anthracycline | OriginalPaper

    Long-term cardiac effects of modern treatment for Hodgkin’s lymphoma

    Hodgkin’s lymphoma (HL) is a hematological malignancy that affects both children and young adults. Modern treatments of HL have greatly improved outcomes and most patients are now being cured, with 5-year survival following multi-agent …

  4. Open Access 01-12-2024 | Non-Hodgkin Lymphoma | OriginalPaper

    Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma

    Non-Hodgkin lymphoma is one of the most common cancers, with its incidence ranking eighth and tenth among men and women, respectively. Countries with a high human development index have higher incidence rates than countries with a low human …

  5. Open Access 20-04-2024 | Hodgkin Lymphoma | Online First

    A pilot randomized controlled trial of an online intervention for Hodgkin lymphoma survivors to increase knowledge about late effects and recommended screening

    Hodgkin lymphoma (HL) affects approximately 9000 young adults and children annually in the United States, with cure rates exceeding 80% [ 1 , 2 ]. Although mortality rates for HL have decreased over the last several decades, survivors are at risk …

  6. Open Access 08-04-2024 | Non-Hodgkin Lymphoma | Online First

    Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas

    The conditioning regimen is an important part of autologous hematopoietic stem cell transplantation (ASCT). We explored the efficacy and safety of an optimized BEAC (adjusted-dose, intermediate-dose cytarabine and reduced-dose cyclophosphamide …

  7. Open Access 01-12-2024 | Diffuse Large B-Cell Lymphoma | OriginalPaper

    MNDA expression and its value in differential diagnosis of B-cell non-Hodgkin lymphomas: a comprehensive analysis of a large series of 1293 cases

    Myeloid nuclear differentiation antigen (MNDA) was initially detected in human promyelocytic cell lines [ 1 , 2 ] and used as a marker for myeloid neoplasms [ 3 , 4 ]. Subsequently, Miranda et al. identified a low level of MNDA expression in a …

  8. Open Access 01-12-2024 | Hodgkin Lymphoma | OriginalPaper

    Vogt-Koyanagi-Harada disease developed during chemotherapy for Hodgkin lymphoma: a case report

    Ocular manifestations are known for non-Hodgkin lymphoma, but are rare for Hodgkin lymphoma. An ocular manifestation is uveitis, which is a general term for inflammatory diseases that occur in uveal tissue, such as the iris, ciliary body, and …

  9. 20-03-2024 | Hodgkin Lymphoma | News | Article

    Doxorubicin use may increase breast cancer risk in adult Hodgkin’s lymphoma survivors

    Adolescent and adult survivors of Hodgkin’s lymphoma have a higher risk for developing breast cancer if they receive doxorubicin than if they do not.

  10. Open Access 23-03-2024 | Hodgkin Lymphoma | Online First

    Post-marketing surveillance of the safety and effectiveness of nivolumab for classic Hodgkin lymphoma in Japan

    Nivolumab was approved for relapsed/refractory classic Hodgkin lymphoma (cHL) in Japan in 2016. After its approval, a prospective, non-interventional, observational post-marketing surveillance was initiated to evaluate the safety and effectiveness …

  11. Open Access 01-12-2024 | Transthoracic Echocardiography | OriginalPaper

    Multiple thrombi mimicking metastases in the right atrium of patients with non-Hodgkin’s lymphoma diagnosed by multimodal cardiac imaging: one case report

    Right-side heart thrombus can be found incidentally on routine TTE. Its early and accurate diagnosis is beneficial to clinical management. Accurate diagnosis of cardiac thrombus often requires more than one imaging method. Echocardiography is the …

  12. 02-03-2024 | Mantle Cell Lymphoma | OriginalPaper

    Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still a potentially curative option for B-cell Non-Hodgkin Lymphoma (B-NHL) in the modern immunotherapy era. The objective of this study was to analyze long-term outcomes of …

  13. Open Access 01-12-2024 | Brentuximab vedotin | OriginalPaper

    Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial

    Classical Hodgkin lymphoma (cHL) typically exhibits a favorable response to conventional treatments, leading to curative outcomes in a significant proportion of patients. However, an estimated 10 to 15% of patients display resistance to initial …

  14. 02-04-2024 | Maintenance Therapy | Online First

    Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma

    Chimeric antigen receptor (CAR)-T cells therapy offers unprecedented efficacy for patients with hematologic malignancies. CD19 CAR-T cells have been approved as the standard of care in relapsed/refractory (r/r) diffuse large B-cell lymphoma

  15. Open Access 01-04-2024 | CAR T-Cell Therapy | Letter

    Monozygotic Twins with MAGT1 Deficiency and Epstein–Barr virus-positive Classic Hodgkin Lymphoma Receiving anti-CD30 CAR T-cell Immunotherapy: A case Report

    Epstein-Barr virus (EBV)-positive classical Hodgkin lymphoma (cHL) is the most common malignancy in patients with “X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia” (XMEN). Aberrant expression of MAGT1 leads to XMEN, a …

  16. Open Access 01-12-2024 | Human Immunodeficiency Virus | OriginalPaper

    Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China

    Little is known about the outcome for HIV-associated Hodgkin lymphoma (HIV-HL) as this is less common than HIV-negative lymphoma. Therefore, we performed a multi-center study to analyze the clinical characteristics and outcomes of HIV-HL patients …

  17. 05-01-2024 | Lymphoma | OriginalPaper

    A Case of Medullary Carcinoma of Colon Morphologically Resembling Non-Hodgkin’s Lymphoma

    Medullary carcinoma of the colon is an unusual and unique histologic subtype of colorectal cancer. It is strongly associated with microsatellite instability, most commonly loss of MLH1 indicative of deficient mismatch repair proteins. Diagnosis is …

  18. Open Access 13-10-2023 | Non-Hodgkin Lymphoma | Online First

    Correction to: Mediastinal large B cell lymphoma and surrounding gray areas: a report of the lymphoma workshop of the 20th meeting of the European Association for Haematopathology

  19. 20-12-2023 | Non-Hodgkin Lymphoma | OriginalPaper

    Prognostic significance of serum monoclonal proteins based on immunofixation electrophoresis in B-cell non-Hodgkin lymphoma

    The presence of serum monoclonal components has been associated with poor outcomes in various hematological malignancies. The current study focused on exploring its prognostic role in B-cell non-Hodgkin lymphoma. Our study represented 314 patients …

  20. 14-02-2024 | Hodgkin Lymphoma | Online First

    Prognostic value of baseline and interim [18F]FDG PET metabolic parameters in pediatric Hodgkin’s lymphoma

    Hodgkin lymphoma (HL) stands as a significant concern in pediatric oncology, yet it is noteworthy for its high curability, with a 5-year overall survival (OS) rate exceeding 90% [ 1 – 3 ]. Given the favorable outcomes, the emphasis has increasingly …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.